Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells

Glycobiology

Volumn 19, Issue 7, 2009, Pages 735-742

  Basappa, ^a,f   Murugan, Sengottuvelan ^a   Sugahara, Kazuki N ^b,c   Lee, Chun Man ^b,d   ten Dam, Gerdy B ^e   Van Kuppevelt, Toin H ^e   Miyasaka, Masayuki ^b   Yamada, Shuhei ^a   Sugahara, Kazuyuki ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OSAKA UNIVERSITY HOSPITAL   (Japan)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f BANGALORE UNIVERSITY   (India)

Author keywords

Chondroitin sulfate; Glycosaminoglycan; Osteosarcoma; Sulfation; Tumor

Indexed keywords

ANTIBODY; CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; CHONDROITIN SULFATE; CHONDROITIN SULFATE E; DERMATAN SULFATE; EPITOPE; GD3G7 ANTIBODY; GLYCOSAMINOGLYCAN; HEPARIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARBOHYDRATE ANALYSIS; CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER NODULE; LIVER TUMOR; LM8 CELL LINE; LM8G7 CELL LINE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ANIMALS; ANTIBODIES, NEOPLASM; CELL ADHESION; CHONDROITIN SULFATES; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED C3H; OSTEOSARCOMA; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE; MUS;

EID: 66249124614     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwp041     Document Type: Article

References (48)

1. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S, Yoshikawa H. 1998. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer. 76:418-422.
2. Baba Y, Iyama KI, Hirashima K, Nagai Y, Yoshida N, Hayashi N, Miyanari N, Baba H. 2008. Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation. Br J Cancer. 98:974-980.
3. Blackhall FH, Merry CL, Davies EJ, Jayson GC. 2001. Heparan sulfate proteoglycans and cancer. Br J Cancer. 19:1094-1098.
4. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. 2001. Heparin and cancer revisited: Mechanistic connections involving platelets, Pselectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA. 98:3352-3357.
5. Chu CL, Goerges AL, Nugent MA. 2005. Identification of common and specific growth factor binding sites in heparan sulfate proteoglycans. Biochemistry. 44:12203-12213.
6. Deepa SS, Umehara Y, Higashiyama S, Itoh N, Sugahara K. 2002. Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues. J Biol Chem. 277:43707-43716.
7. Denholm EM, Lin YQ, Silver PJ. 2001. Anti-tumor activities of chondroitinase AC and chondroitinase B: Inhibition of angiogenesis, proliferation and invasion. Eur J Pharmacol. 416:213-221.
8. Dietrich CP. 1984. A model for cell-cell recognition and control of cell growth mediated by sulfated glycosaminoglycans. Braz J Med Biol Res 17:5-15.
9. Esko JD, Selleck SB. 2002. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 71:435-471.
10. Fidler IJ. 2003. The pathogenesis of cancer metastasis: The "seed and soil" hypothesis revisited. Nat Rev Cancer. 3:453-458.
11. Fidler IJ, Nicolson GL. 1976. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst. 57:1199-11202.
12. Gallagher JT. 1989. The extended family of proteoglycans: Social residents of the pericellular zone. Curr Opin Cell Biol. 1:1201-1218.
13. Hibino S, Shibuya M, Hoffman MP, Engbring JA, Hossain R, Mochizuki M, Kudoh S, Nomizu M, Kleinman HK. 2005. Laminin alpha5 chain metastasis- and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44. Cancer Res 65:10494-10501.
14. Iida J, Meijne AM, Knutson JR, Furcht LT, McCarthy JB. 1996. Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin Cancer Biol. 7:155-162.
15. Iida J, Meijne AM, Oegema TR Jr, Yednock TA, Kovach NL, Furcht LT, McCarthy JB. 1998. A role of chondroitin sulfate glycosaminoglycan binding site in alpha4beta1 integrin-mediated melanoma cell adhesion. J Biol Chem. 273:5955-5962.
16. Iozzo RV. 1998. Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem. 67:609-652.
17. Iozzo RV, San Antonio JD. 2001. Heparan sulfate proteoglycans: Heavy hitters in the angiogenesis arena. J Clin Invest. 108:349-355.
18. Jayne DG, Perry SL, Morrison E, Farmery SM, Guillou PJ. 2000. Activated mesothelial cells produce heparin-binding growth factors: Implications for tumour metastases. Br J Cancer. 82:1233-1238.
19. Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT. 1998. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem. 273:51-57.
20. Kawashima H, Atarashi K, Hirose M, Hirose J, Yamada S, Sugahara K, Miyasaka M. 2002. Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines. J Biol Chem. 277:12921-12930.
21. Kinoshita A, Sugahara K. 1999. Microanalysis of glycosaminoglycan-derived oligosaccharides labeled with a fluorophore 2-aminobenzamide by high-performance liquid chromatography: Application to disaccharide composition analysis and exosequencing of oligosaccharides. Anal Biochem. 269:367-378.
22. Kinoshita A, Yamada S, Haslam SM, Morris HR, Dell A, Sugahara K. 1997. Novel tetrasaccharides isolated from squid cartilage chondroitin sulfate E contain unusual sulfated disaccharide units GlcA(3-O sulfate)beta1- 3GalNAc(6-O-sulfate) or GlcA(3-O sulfate)beta1-3GalNAc. J Biol Chem. 272:19656-19665.
23. Kure S, Yoshie O, Aso H. 1987. Metastatic potential of murine B16 melanoma correlates with reduced surface heparan sulfate glycosaminoglycan. Jpn J Cancer Res. 78:1238-1245.
24. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M. 2002. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 62:4282-4288.
25. Li F, Shetty AK, Sugahara K. 2007. Neuritogenic activity of chondroitin/ dermatan sulfate hybrid chains of embryonic pig brain and their mimicry from shark liver. Involvement of the pleiotrophin and hepatocyte growth factor signaling pathways. J Biol Chem. 282:2956-2966.
26. Li F, ten Dam GB, Murugan S, Yamada S, Hashiguchi T, Mizumoto S, Oguri K, Okayama M, van Kuppevelt TH, Sugahara K. 2008. Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells. J Biol Chem. 283:34294-34304.
27. Liotta LA. 1986. Tumor invasion and metastases - Role of the extracellular matrix. Cancer Res. 46:1-7.
28. Lv H, Yu G, Sun L, Zhang Z, Zhao X, Chai W. 2007. Elevate level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma. Oncology. 72:347-356.
29. Miyazaki T, Miyauchi S, Tawada A, Anada T, Matsuzaka S, Suzuki O. 2008. Oversulfated chondroitin sulfate-E binds to BMP-4 and enhances osteoblast differentiation. J Cell Physiol. 217:769-777.
30. Mundhenke C, Meyer K, Drew S, Friedl A. 2002. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol. 160:185-194.
31. Munesue S, Yoshitomi Y, Kusano Y, Koyama Y, Nishiyama A, Nakanishi H, Miyazaki K, Ishimaru T, Miyaura S, Okayama M, et al. 2007. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem. 282:28164-28174.
32. Nakanishi H, Oguri K, Yoshida K, Itano N, Takenaga K, Kazama T, Yoshida A, Okayama M. 1992. Structural differences between heparan sulphates of proteoglycan involved in the formation of basement membranes in vivo by Lewis-lung-carcinoma-derived cloned cells with different metastatic potentials. Biochem J. 288:215-224.
33. Purushothaman A, Fukuda J, Mizumoto S, ten Dam GB, van Kuppevelt TH, Kitagawa H, Mikami T, Sugahara K. 2007. Functions of chondroitin sulfate/ dermatan sulfate chains in brain development. Critical roles of E and iE disaccharide units recognized by a single chain antibody GD3G7. J Biol Chem. 282:19442-19452.
34. Redini F, Moczar E, Poupon MF. 1986. Cell surface glycosaminoglycans of rat rhabdomyosarcoma lines with different metastatic potentials and of non-malignant rat myoblasts. Biochim Biophys Acta. 883:98-105.
35. Robinson J,Viti M,Höök M. 1984. Structure and properties of an under-sulfated heparan sulfate proteoglycan synthesized by a rat hepatoma cell line. J Cell Biol. 98:946-953.
36. Saito H, Yamagata T, Suzuki S. 1968. Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates. J Biol Chem. 243:1536-1542.
37. Sanderson RD. 2001. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol. 12:89-98.
38. Sugahara K, Mikami T. 2007. Chondroitin/dermatan sulfate in the central nervous system. Curr Opin Struct Biol. 17:536-545.
39. Sugahara K, Okumura Y, Yamashina I. 1989. The Engelbreth-Holm-Swarm mouse tumor produces undersulfated heparan sulfate and oversulfated galactosaminoglycans. Biochem Biophys Res Commun. 162:189-197.
40. Sugahara KN, Hirata T, Tanaka T, Ogino S, Takeda M, Terasawa H, Shimada I, Tamura J, ten Dam GB, van Kuppevelt TH, et al. 2008. Chondroitin sulfate E fragments enhance CD44 cleavage and CD44-dependent motility in tumor cells. Cancer Res. 68:7191-7199.
41. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. 1995. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:3964-3968.
42. Tanaka Y, Nakayamada S, Fujimoto H, Okada Y, Umehara H, Kataoka T, Minami Y. 2002. H-Ras/mitogen-activated protein kinase pathway inhibits integrin-mediated adhesion and induces apoptosis in osteoblasts. J Biol Chem. 277:21446-21452.
43. ten Dam GB, van de Westerlo EM, Purushothaman A, Stan RV, Bulten J, Sweep FC, Massuger LF, Sugahara K, van Kuppevelt TH. 2007. Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. Am J Pathol. 171:1324-1333.
44. Theocharis AD. 2002. Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. Biochim Biophys Acta. 1588:165-172.
45. Timar J, Ladanyi A, Lapis K, Moczar M. 1992. Differential expression of proteoglycans on the surface of human melanoma cells characterized by altered experimental metastatic potential. Am J Pathol. 141:467-474.
46. Tóvásari J, Paku S, Rásó E, Pogáany G, Kovalszky I, Ladányi A, Lapis K, Tímár J. 1997. Role of sinusoidal heparan sulfate proteoglycan in liver metastasis formation. Int J Cancer. 71:825-831.
47. Weis S, Cui J, Barnes L, Cheresh D. 2004. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 167:223-229.
48. Yamada S, Sugahara K. 2008. Potential therapeutic application of chondroitin sulfate/dermatan sulfate. Curr Drug Discov Technol. 5:289-301.